Sold as Cysview. Every FDA application for this active ingredient.
As of Nov 22, 2026, FDA lists 1 application for Hexaminolevulinate hydrochloride (sold as Cysview), first approved May 28, 2010, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Cysview | Part B | $286K | +25% | 159 |
| APL-1702 Photodynamic Therapy in Patients With High-Risk HPV-Positive Cervical Intraepithelial Neoplasia Grade II/III (CIN2/3)Cervical Intraepithelial Neoplasia Grade 2/3, Human Papillomavirus Infection · Xiangya Hospital of Central South University | Not applicable | Recruiting | Nov 18, 2026 |
| Exploratory Study of the Efficacy of HAL-PDT in CIN 3Cervical Intraepithelial Neoplasia Grade 3 · Tongji Hospital | Phase 2 | Not yet recruiting | Oct 23, 2026 |
| RWS of PDT for CIN 2Cervical Intraepithelial Neoplasia Grade 2 (CIN2) · Tongji Hospital | — | Not yet recruiting | Oct 21, 2026 |
| Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)Cervical Intraepithelial Neoplasia, Papillomavirus Infections · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Jun 25, 2026 |
| HAL-PDT for Cervical Intraepithelial Neoplasia Grade 2Cervical Intraepithelial Neoplasia Grade 2 (CIN2) · Peking Union Medical College Hospital | — | Not yet recruiting | Jun 8, 2026 |
| Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma · University of Roma La Sapienza | Phase 4 | Recruiting | Jul 27, 2023 |
| Blue Light Cystoscopy With Cysview® RegistryBladder Cancer · Photocure | — | Recruiting | Jan 21, 2016 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA